Core Insights - Boston Scientific (BSX) is strategically positioned to benefit from the expanding cardiovascular devices market, which is projected to grow from $72.83 billion in 2023 at a CAGR of 7.3% from 2024 to 2029 [1][2] - The company's strong performance in Q1 2025, with a revenue increase of 22.2% and adjusted EPS growth of 34%, reflects its leadership in the cardiovascular segment [6][7] - BSX's stock has outperformed the broader Medical Product industry and key competitors, with a 31.8% increase over the past year [3] Market Performance - The cardiovascular devices market is experiencing growth due to aging demographics, minimally invasive procedures, and technological innovations [2] - Boston Scientific's Electrophysiology business has seen organic growth of 145%, making it the second-largest player in this space [8] - The company reported a 26.2% year-over-year increase in cardiovascular segment sales, with U.S. revenues rising by 31% [6][9] Financial Outlook - For full-year 2025, Boston Scientific raised its organic revenue growth guidance to 12-14% and expects adjusted EPS of $2.87-$2.94, indicating a year-over-year growth of 14-17% [11] - The Zacks Consensus Estimate for BSX's 2025 sales and EPS suggests a year-over-year improvement of 16.4% and 15.9%, respectively [12] Product Performance - The WATCHMAN device sales grew by 24% year over year, supported by procedural growth and new product versions [10] - The FARAPULSE system is gaining traction globally, contributing to the rapid expansion of BSX's market share in Electrophysiology [8][9] Competitive Positioning - Boston Scientific's shares are trading at a forward P/E of 33.31X, which is above the industry average of 21.29X, indicating a premium valuation [15] - The company is expected to continue delivering shareholder value through strong operational performance and growth in key segments [17][18]

ALPHARETTA, Ga., June 9, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) a leading medical technology company focused on delivered innovative healthcare solutions, today announced the appointment of Camille Chang Gilmore as senior vice president and chief human resources officer. Camille Chang Gilmore Camille Chang Gilmore In this role, Gilmore will lead all aspects of Avanos' people strategy, including talent acquisition and development, workforce planning, leadership development and employee experi ...

Core Viewpoint - Boston Scientific (BSX) has received an upgrade to a Zacks Rank 2 (Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on a company's changing earnings picture, specifically the consensus of EPS estimates from sell-side analysts [1][2]. - Changes in future earnings potential, reflected in earnings estimate revisions, are strongly correlated with near-term stock price movements, particularly due to institutional investors' reliance on these estimates for valuation [4][6]. Business Outlook and Investor Sentiment - The rising earnings estimates and the Zacks rating upgrade for Boston Scientific indicate an improvement in the company's underlying business, suggesting that investors may respond positively by pushing the stock price higher [5][10]. - Boston Scientific is projected to earn $2.91 per share for the fiscal year ending December 2025, representing a year-over-year change of 15.9%, with a 2.3% increase in the Zacks Consensus Estimate over the past three months [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 (Strong Buy) stocks historically generating an average annual return of +25% since 1988 [7][9]. - The upgrade of Boston Scientific to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10].

Core Insights - Emerging markets are crucial for Boston Scientific Corporation's (BSX) growth strategy, with a 9.8% year-over-year operational sales growth in Q1 2025 despite geopolitical challenges [1][8] - The medical device industry is experiencing strong growth opportunities in emerging markets, driven by trends such as preventive healthcare and digital health adoption [2] - Boston Scientific's sustained investment and localized strategies position it well to capture future growth in these high-potential regions [3] Emerging Market Performance - BSX's emerging market operations delivered robust sales growth of approximately 9.8% year over year in Q1 2025, supported by favorable economic trends and expanding healthcare infrastructure [1][8] - India’s medical device market is projected to grow from $15.35 billion in 2023 to $20.51 billion by 2029, reflecting a CAGR of 5.35% [2] - China and Brazil are highlighted as key markets due to their large populations and expanding economies, with Southeast Asian countries also gaining importance [2] Competitive Landscape - Competition in emerging markets is intense, with Abbott Laboratories and Medtronic actively expanding their global reach [4] - Abbott's Established Pharmaceuticals Division, focused on emerging markets, reported high single-digit organic growth in Q1 2025, driven by strong demand across Asia, Latin America, and the Middle East [5] - Medtronic generated nearly 49% of its revenues from international markets, with mid-single-digit growth in its emerging market business, particularly in India and Southeast Asia [6] Financial Performance - BSX shares have increased by 35.8% over the past year, outperforming the industry growth of 9.6% and the S&P 500's growth of 12.2% [7][8] - The company trades at a forward price-to-earnings ratio of 33.69, which is above the industry average of 21.73 [9] - The Zacks Consensus Estimate for BSX's earnings has been rising, indicating positive sentiment among analysts [10]

Core Viewpoint - TELA Bio, Inc. has appointed Jeffrey Blizard as President to enhance its leadership team and drive the next phase of growth in the medical technology sector, particularly in soft-tissue reconstruction solutions [1][2]. Leadership Changes - Jeffrey Blizard, previously on TELA Bio's Board of Directors, brings extensive industry experience and a successful track record from his role as Global Head of Surgical Sales at Abiomed, contributing to significant growth in that division [1][2]. - The CEO of TELA Bio, Antony Koblish, emphasized that Blizard's leadership will enhance the company's competitive edge and commercial performance in a dynamic market [2]. Company Overview - TELA Bio, Inc. is focused on innovative technologies for soft-tissue reconstruction, aiming to optimize clinical outcomes by preserving and restoring the patient's anatomy [3]. - The company is committed to providing advanced, economically effective solutions that leverage the patient's natural healing response while minimizing reliance on permanent synthetic materials [3].

Industry Overview - The medical device industry is central to delivering effective healthcare outcomes through advanced technology and engineering [1] - Key innovations include minimally invasive surgical tools, wearable technologies, and enhanced robotic capabilities [1] Company Highlights - Several standout companies are leading the advancements in the medical device sector [1]

Core Viewpoint - Boston Scientific Corporation has decided to cease global sales and regulatory efforts for its ACURATE neo2 and Prime aortic valve systems due to increased demands from health authorities making the process too costly [1][2][3] Group 1: Company Actions - The company has halted its pursuit of FDA approval for the ACURATE valve systems [2][3] - Boston Scientific based its decision on recent discussions with regulators, noting that the additional resources required to meet new clinical and regulatory demands are prohibitive [3] Group 2: Financial Outlook - Despite the setback, Boston Scientific remains confident in its broader portfolio and is on track to meet its financial targets for the quarter and full year [2] - The company has not reaffirmed its GAAP EPS guidance for the second quarter and full year 2025, but estimates 2025 GAAP earnings of $1.86-$1.93 per share and second-quarter earnings of $0.45 to $0.47 per share [4] - Boston Scientific forecasts net sales growth of approximately 15%-17% in 2025 on a reported basis and around 12%-14% on an organic basis, adjusting previous guidance [5]

Company Performance - Boston Scientific achieved 16.5% organic growth and 22% EPS growth in 2024, with a strong start to 2025 showing 18% organic growth and 34% EPS growth in Q1 [3][4]. Strategic Focus - The company aims to maintain high execution standards and strives to be a leading medtech company, with a commitment to achieving this goal over the next five years [4].

Financial Data and Key Metrics Changes - Boston Scientific reported 16.5% organic growth and 22% EPS growth for FY 2024, with a strong start to FY 2025 showing 18% organic growth and 34% EPS growth in Q1 [1][2] - The company raised its full-year guidance to 12-14% organic growth and enhanced its EPS and margin profile despite tariff impacts [4][5] Business Line Data and Key Metrics Changes - The weighted average market growth rate for Boston Scientific has improved from around 1% years ago to approximately 8% currently, driven by a focus on innovation and faster-growing markets [7][8] - The discontinuation of the Accurate neo two product is expected to impact full-year sales by about $200 million, but the company maintains its guidance for Q2 and full-year sales and adjusted EPS [15][16] Market Data and Key Metrics Changes - The overall health of the med tech market remains resilient, with Boston Scientific positioned in high-growth markets such as electrophysiology (EP) and left atrial closure (LAC) [6][8] - The company has successfully navigated macro headwinds, including tariffs and regulatory changes, maintaining strong patient volume due to aging demographics [9][10] Company Strategy and Development Direction - Boston Scientific aims to be the highest-performing med tech company, focusing on enhancing its market growth rate and delivering differentiated results over the next five years [4][21] - The company is investing heavily in its portfolio to position itself for future growth, particularly in the EP and LAC markets [21][66] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate macroeconomic challenges and emphasized the strength of its global team and supply chain [10][12] - The company anticipates continued growth in the FerriPulse product line, with expectations for PFA to exceed 60% of global AF ablations by 2026 [48][49] Other Important Information - The company has a robust venture capital portfolio that supports its growth strategy, with successful acquisitions contributing to its market position [88][90] - The launch of the FerriPulse product has been described as one of the best in med tech history, with significant market potential and positive feedback from healthcare professionals [35][39] Q&A Session Summary Question: Can you provide an update on the tariff situation? - The company has seen better news regarding tariffs, which is beneficial for its operations, and will provide updates in the second quarter [12][13] Question: What is the impact of discontinuing the Accurate neo two product? - The decision was made due to increased regulatory requirements, but the company expects to meet its sales and EPS guidance despite the financial impact [15][16] Question: How does the company view its growth prospects in the next few years? - Management believes the company will exceed its previous growth guidance and is focused on enhancing its market position and product portfolio [20][21] Question: What is the significance of the CHAMPION trial for WATCHMAN? - The CHAMPION trial aims to demonstrate the efficacy of WATCHMAN compared to oral anticoagulants, which could significantly expand the market for left atrial appendage closure [77][78] Question: How does Boston Scientific plan to compete in interventional cardiology without a TAVR asset? - The company is focusing on its strengths in coronary interventions and has a comprehensive portfolio that addresses unmet needs in the market [79][82]

Company Overview - Glucotrack, Inc. is focused on the design, development, and commercialization of novel technologies for people with diabetes [5] - The company is currently developing a long-term implantable continuous blood glucose monitoring (CBGM) system [5][6] Leadership Addition - Victoria E. Carr-Brendel, PhD, has been elected to Glucotrack's Board of Directors effective May 22, 2025 [1] - Dr. Carr-Brendel brings extensive experience in medical devices and implantable technologies, having held leadership roles at various companies including Vicarious Surgical Inc. and Sonova Group [2][3] Technology Development - Glucotrack's CBGM is designed as a long-term implantable system that provides continuous blood glucose monitoring for up to three years [3][6] - The system measures glucose directly from blood, offering real-time readings without the lag time associated with traditional continuous glucose monitoring systems [3] Strategic Importance - Dr. Carr-Brendel expressed her commitment to contributing to Glucotrack's strategic and clinical milestones, emphasizing the potential of the CBGM to address unmet needs for diabetes management [3]